Chart Events
Performance Outlook
| Previous Close | 9.53 |
| Open | 9.62 |
| Bid | 9.58 x 4000 |
| Ask | 9.59 x 1200 |
| Day's Range | 9.55 - 9.67 |
| 52 Week Range | 8.42 - 12.40 |
| Volume | |
| Avg. Volume | 9,393,530 |
| Market Cap | 11.599B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | 0.48 (3.96%) |
| Ex-Dividend Date | Nov 22, 2022 |
| 1y Target Est | 15.11 |
- Benzinga
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ: VTRS) – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). Aurobindo Pharma and Viatris will manufacture in India. Cipla Limited will manufacture in India and plans to manufacture in South Africa too. ViiV Healthcare is majority owned by GSK Plc (NYSE: GSK), with Pfize
- GlobeNewswire
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis; $10 Million Milestone Linked to Approval Oral APX3330 Achieved Statistical Significance on a Potential Registration Endpoint for Diabetic Retinopathy in ZETA-1 Trial; End-of-Phase 2 FDA Meeting Planned FARMINGTON HILLS, Mich
- Zacks
Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
